Bio-Rad Laboratories (BIO.B) vs DexCom (DXCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed DexCom (DXCM) over the past year, gaining 28.2% versus a gain of 24.5%. Over five years, DXCM leads with a -38.0% price change compared with -50.5% for BIO.B. DexCom is the larger company by market cap ($31.85 billion vs $9.76 billion), about 3.3 times the size.
On valuation, DexCom trades at a lower trailing P/E (33.5x vs 46.3x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 17.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | DXCM |
|---|---|---|
| Share price | $365.08 | $84.41 |
| Market cap | $9.76B | $31.85B |
| 1-day change | 0.00% | +0.13% |
| YTD return | +17.50% | +27.18% |
| 1-year return | +28.15% | +24.54% |
| 5-year return | -50.54% | -37.99% |
| P/E ratio (TTM) | 46.27 | 33.50 |
| Forward P/E | — | 26.99 |
| EPS (TTM) | $7.89 | $2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $4.66B |
| Revenue growth (YoY) | +0.65% | +15.60% |
| Net income (latest FY) | $759.90M | $836.30M |
| Gross margin | 51.87% | 60.10% |
| Operating margin | 1.83% | 19.56% |
| Net margin | 29.42% | 17.94% |
| 52-week high | $365.08 | $92.59 |
| 52-week low | $244.54 | $54.11 |
| Distance from 52-week high | 0.00% | -8.83% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +14.00% |
| Average volume | 6 | 4.43M |
| Shares outstanding | 5.06M | 377.36M |
| Employees | 7,450 | 11,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 3.3 times larger than Bio-Rad Laboratories by market value ($31.85B vs $9.76B).
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 33.5x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 17.9 cents for DexCom.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +0.65%).
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Healthcare · Medical Devices · 11,000 employees
BIO.B vs DXCM FAQ
Which is bigger, Bio-Rad Laboratories or DexCom?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $9.76B for Bio-Rad Laboratories (BIO.B).
Which stock has performed better over the past year, BIO.B or DXCM?
BIO.B returned +28.15% over the past 12 months, compared with +24.54% for DXCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or DXCM?
DXCM has the lower trailing P/E at 33.5, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bio-Rad Laboratories and DexCom in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.